VTVT

vTv Therapeutics Inc. NASDAQ

Healthcare ·Biotechnology ·US · vtvtherapeutics.com

$32.50

Mkt Cap $85.1M

52w Low $14.00 61.7% of range 52w High $44.00

50d MA $36.52 200d MA $28.60

P/E (TTM) -9.9x

EV/EBITDA -7.6x

P/B 4.1x

Debt/Equity 0.0x

ROE -41.9%

P/FCF -13.3x

RSI (14) —

ATR (14) —

Beta 0.40

50d MA $36.52

200d MA $28.60

Avg Volume 55.0K

About

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addr…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 10, 2026	AMC	-0.98	-0.58	+40.8%	35.02	+9.8%	+0.2%	-3.7%	-5.0%	+8.9%	+4.8%	—
Nov 6, 2025	AMC	-0.97	-1.08	-11.3%	25.47	-4.6%	+2.2%	+9.9%	+14.3%	+21.7%	+22.8%	—
Aug 12, 2025	AMC	-0.85	-0.92	-8.2%	14.49	-3.4%	-3.2%	+5.6%	+6.6%	+7.1%	+7.1%	—
May 15, 2025	AMC	-0.73	-0.77	-5.5%	22.41	-0.0%	-6.2%	-5.2%	-7.4%	-10.8%	-13.2%	—
Mar 20, 2025	AMC	-0.87	-0.55	+36.8%	17.61	-5.1%	-5.5%	-1.4%	-2.3%	-2.3%	-2.6%	—
Nov 12, 2024	AMC	-3.60	-0.88	+75.6%	13.91	-0.8%	+7.1%	+12.4%	+25.1%	+21.5%	+18.1%	—
Aug 8, 2024	AMC	-3.20	-0.81	+74.7%	13.49	-1.9%	-1.8%	-3.6%	-2.3%	-1.3%	+0.0%	—
May 9, 2024	AMC	-3.20	-1.17	+63.4%	26.83	-3.1%	-3.1%	-3.5%	-3.2%	-3.5%	+3.9%	—
Mar 13, 2024	AMC	-2.80	-1.67	+40.4%	16.04	+0.0%	+6.3%	+12.2%	+25.4%	+30.3%	+66.3%	—
Nov 9, 2023	AMC	-3.20	-3.20	+0.0%	15.20	-5.3%	-6.8%	-6.3%	-7.9%	-7.6%	-4.7%	—
Aug 11, 2023	AMC	-0.07	-2.80	-3900.0%	28.84	-2.2%	+2.6%	-1.1%	-1.2%	-2.2%	-6.9%	—
May 11, 2023	AMC	-3.20	-2.40	+25.0%	35.60	+0.0%	-5.5%	-3.5%	+1.1%	+6.4%	+4.5%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 11	BTIG	Maintains	Buy → Buy	—	$35.02	$38.44	+9.8%	+0.2%	-3.7%	-5.0%	+8.9%	+4.8%
Jan 27	BTIG	Maintains	Buy → Buy	—	$33.86	$34.44	+1.7%	+0.4%	+0.5%	+0.9%	+4.6%	+13.1%
Dec 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$34.72	$36.48	+5.1%	+3.7%	+5.6%	+8.0%	+6.6%	+9.2%
Aug 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.49	$14.00	-3.4%	-3.2%	+5.6%	+6.6%	+7.1%	+7.1%
Mar 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$37.60	$36.40	-3.2%	-4.8%	-10.6%	-14.7%	-23.5%	-16.9%
Aug 16	Northland Capital Markets	Maintains	Outperform → Outperform	—	$54.80	$52.40	-4.4%	-11.7%	-5.8%	-10.9%	-10.9%	-16.1%
Feb 18	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$28.48	$30.80	+8.1%	+19.2%	+8.1%	+1.1%	+5.3%	+13.8%
Feb 10	H.C. Wainwright	Maintains	Buy → Buy	—	$84.00	$153.60	+82.9%	+52.4%	+51.4%	+46.2%	+40.0%	+38.1%
Feb 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$84.00	$153.60	+82.9%	+52.4%	+51.4%	+46.2%	+40.0%	+38.1%
May 30	H.C. Wainwright	Maintains	Buy → Buy	—	$70.00	$72.80	+4.0%	+4.0%	+4.6%	-3.4%	-2.9%	-4.6%
May 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	$70.00	$72.80	+4.0%	+4.0%	+4.6%	-3.4%	-2.9%	-4.6%
May 5	Northland Capital Markets	Upgrade	Market Perform → Outperform	—	—	—	—	—	—	—	—	—
Apr 10	Stifel Nicolaus	Downgrade	Buy → Hold	—	$130.40	$40.40	-69.0%	-78.1%	-78.2%	-75.5%	-76.7%	-74.5%
Apr 10	PiperJaffray	Downgrade	Overweight → Neutral	—	$130.40	$40.40	-69.0%	-78.1%	-78.2%	-75.5%	-76.7%	-74.5%
Apr 10	Northland Securities	Downgrade	Outperform → Market Perform	—	$130.40	$40.40	-69.0%	-78.1%	-78.2%	-75.5%	-76.7%	-74.5%
Apr 9	Northland Capital Markets	Downgrade	Outperform → Market Perform	—	$136.80	$137.60	+0.6%	-4.7%	-79.1%	-79.2%	-76.6%	-77.8%
Apr 9	Piper Sandler	Downgrade	Overweight → Neutral	—	$136.80	$137.60	+0.6%	-4.7%	-79.1%	-79.2%	-76.6%	-77.8%
Apr 9	Roth Capital	Downgrade	Buy → Neutral	—	$136.80	$137.60	+0.6%	-4.7%	-79.1%	-79.2%	-76.6%	-77.8%
Apr 9	Seaport Global	Downgrade	Buy → Neutral	—	$136.80	$137.60	+0.6%	-4.7%	-79.1%	-79.2%	-76.6%	-77.8%
Apr 9	Stifel	Downgrade	Buy → Hold	—	$136.80	$137.60	+0.6%	-4.7%	-79.1%	-79.2%	-76.6%	-77.8%
Mar 29	Seaport Global	Maintains	Buy → Buy	—	$156.40	$169.20	+8.2%	+4.1%	-0.5%	+3.3%	-1.8%	-5.6%
Feb 8	Northland Securities	Maintains	Outperform → Outperform	—	$270.40	$282.00	+4.3%	+0.9%	-4.0%	-8.7%	-5.8%	-6.1%
Sep 26	H.C. Wainwright	Maintains	Buy → Buy	—	$286.80	$289.20	+0.8%	+0.8%	+1.0%	+0.8%	-0.3%	+0.3%
Dec 17	Janney Capital	Maintains	Buy → Buy	—	$258.80	$266.00	+2.8%	-1.2%	+0.6%	+2.2%	+11.1%	+16.4%
Sep 4	Canaccord Genuity	Maintains	Buy → Buy	—	$380.00	$367.60	-3.3%	-1.9%	+1.5%	-2.9%	-5.7%	-3.1%
Aug 24	PiperJaffray	Maintains	Overweight → Overweight	—	$354.00	$318.00	-10.2%	-0.1%	-5.2%	+1.4%	+0.7%	+6.4%
Aug 24	Stifel Nicolaus	Maintains	Buy → Buy	—	$354.00	$318.00	-10.2%	-0.1%	-5.2%	+1.4%	+0.7%	+6.4%

Recent Filings

8-K

Unknown — 8-K Filing

vTv's $20M licensing deal and extended cash runway reduce dilution risk while Phase 3 trial completion approaches mid-2026, potentially supporting stock if efficacy data proves positive.

Mar 10

8-K · 7.01 ! Medium

Unknown — 8-K 7.01: Regulation FD Disclosure

VTVT's real-world evidence from 48,000+ type 1 diabetes patients showing improved glycemic outcomes with technology adoption strengthens its competitive positioning and supports regulatory/reimbursement arguments for its diabetes management solutions.

Mar 10

8-K · 7.01 ! Medium

vTv Therapeutics Inc. -- 8-K 7.01: Regulation FD Disclosure

vTv Therapeutics disclosed an investor presentation that may be updated periodically through future SEC filings, signaling ongoing communication with market participants about company developments.

Feb 26

8-K · 1.01 !! High

vTv Therapeutics Inc. -- 8-K 1.01: Material Agreement

vTv Therapeutics entered a $20 million agreement with Newsoara Biopharma, potentially expanding its pipeline or securing funding for development initiatives.

Feb 2

Data updated apr 27, 2026 8:30am · Source: massive.com